Abstract

The article explores the evolution of antiviral therapy, highlighting key developments and current trends in the field. Antiviral therapy has undergone significant advancements since the discovery of the first antiviral drug in the 1960s. This article delves into the historical context, detailing the classes of antiviral drugs that have emerged over the years, such as nucleoside analogs, protease inhibitors, and entry inhibitors. The review extends to cutting-edge technologies shaping the future of antiviral treatment, including RNA interference, CRISPR-based therapies, and monoclonal antibodies. Despite notable progress, challenges persist, including the rise of drug-resistant strains. The article discusses ongoing research strategies, such as host-targeted therapies and combination approaches, aimed at addressing these challenges. As technology and our understanding of virology continue to advance, the article emphasizes the promising future of antiviral therapy, offering more effective, targeted, and personalized treatments against a spectrum of viral infections. The evolution of antiviral therapies stands as a beacon of hope in the ongoing battle against infectious diseases, shaping a new frontier in medical advancements.